POSTER SESSION 1: Prostate I

---

PP-01Targeted biopsy of the prostate with bio jet 20 cases experience
M.H. Radulescu, T. Clement, E. Parizel (France)

PP-02 Development of Zr-89 PET imaging protocols for prostate cancer using Monte Carlo simulations: Preliminary study
K. Alzimami, S. Sassi, N. Spyrou (Saudi Arabia & United Kingdom)

PP-03 Time-dependent change of blood flow in the prostate treated with high intensity focused ultrasound
S. Shoji, A. Tonooka, A. Hashimoto, M. Nakamoto, N. Fukuda, T. Tomonaga, M. Nakano, Y. Sato, T. Terachi, J. Koike, T. Uchida (Japan)

PP-04 MRI-directed transperineal limited-mapping prostatic biopsies to diagnose prostate cancer: A Scottish experience
A. Mukherjee, S. Morton, S. Fraser, J. Salmond, G. Baxter, H. Leung (United Kingdom)

PP-05 Eligibility to focal therapy in a cohort of patients submitted to stereotactic prostate biopsy with or without MRI fusion
P. Puppo, F. Germinale, F. Bertolotto, M. Raggio (Italy)

PP-06 WITHDRAWN

PP-07 WITHDRAWN

PP-08 WITHDRAWN

PP-09 Learning curve of MRI-ultrasound fusion biopsy: How to accurately target suspicious lesions?
K. Kamoi, K. Okihara, F. Hongo, Y. Naya, T. Nakamura, Y. Naitoh, A. Fujihara, T. Miki (Japan)

PP-10 Prostate MR image generation: The physics behind the magic
B. Greenwood, J. Feller (USA)

PP-11 MRI-based 3D-cancer mapping: Implication for focal cryotherapy 
K. Kamoi, K. Okihara, F. Hongo, Y. Naya, Y. Naitoh, A. Fujihara, T. Ueda, M. Tsuneharu (Japan)

PP-12 Computer aided transperineal optimized prostate (TOP) biopsy for volumetric contour based biopsy core planning
I.V. Popeneciu, T.H. Kuru, J.P. Radtke, P. Zogal, S. Boxler, M. Hohenfellner, G. Sakas, B.A. Hadaschik (Germany & Switzerland)

PP-13 Morphometric analysis of prostate zonal anatomy by magnetic resonance imaging (MRI): Impact on age-related changes  
T. Matsugasumi, O. Ukimura, M. Nakamoto, Y. Yamada, A. Fujihara, D. Toiyama, T. Iwata, S. Ushijima, M. Kanazawa, T. Miki, A.L. de Castro Abreu, S. Palmer, I.S. Gill (USA & Japan)

PP-14 Identification of focal therapy candidates among patients undergoing targeted MR-ultrasound fusion biopsy
C.P. Filson, P. Lieu, D.J.A. Margolis, S. Natarajan, L.S. Marks (USA)

PP-15 3D Acoustic Radiation Force Impulse (ARFI) elasticity imaging of prostate cancer: Correlation between in vivo imaging and whole mount histology
M. Mendez, Z. Miller, M. Palmeri, T. Glass, S. Rosenzweig, A. Buck, J. Madden, T. Polascik, K. Nightingale (USA)

PP-16 MRI-ultrasound fusion targeted biopsies. A single-center prospective study
P. Nevoux, J. Lacoste, T. Rousseau, G. Le Coguic, G. Aillet, E. Potiron (France)

PP-17 Global to Focal – The changing face of prostate cancer diagnosis
H. Lewi, S. Buttle (United Kingdom)

PP-18 Pathological features of the index and non-index lesions in radical prostatectomy specimens: Implications for focal therapy
K. Kanao, K. Kajikawa, I. Kobayashi, M. Sumitomo (Japan)

PP-19 Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy
M. Mendez, R. Gupta, K. Faridi, A. Singh, N. Passoni, K. Garcia-Reyes, J. Madden, T. Polascik (USA)

PP-20 Comparative analysis of transperineal template – Saturation prostate biopsy versus MRI-targeted biopsy with MRI-US fusion-guidance
I.V. Popeneciu, J.P. Radtke, T.H. Kuru, S. Boxler, C. Alt, C. Huettenbrink, T. Klein, S. Steinemann, C. Bergstraesser, M. Roethke, W. Roth, H.-P. Schlemmer, M. Hohenfellner, B.A. Hadaschik (Germany, Switzerland)

PP-21 Use of multiparametric MRI of prostate in active surveillance cohort of patients with localized prostate cancer in large urology group setting
D. Telonis, S. Buckingham, R. Kronhaus, C. Pieczonka, W. Muakkassa, H. Williams, D. Albala, V. Mouraviev (USA)

PP-22 Frequency of unifocal and unilateral lesions in localized prostate cancer in community practice
A. Yi, D. Telonis, S. Buchingham, C. Pieczonka, W. Muakkassa, H. Williams, R. Kronhaus, D. Albala, V. Mouraviev (USA)

PP-23 WITHDRAWN

PP-24 Patient-specific prostate molds to improve correlation of MR and pathologic findings: Margins for focal therapy
A. Priester, J.D. Le, H. Lee, J. Garritano, W. Grundfest, J. Huang, D.J.A. Margolis, L.S. Marks, S. Natarajan (USA)


POSTER SESSION 2: Prostate II

---

PP-25 Focal therapy of localized prostate cancer by Focal One®: First experience
P. Nevoux, E. Potiron, T. Rousseau, G. Le Coguic, G. Aillet, J. Lacoste (France)
 
PP-26 Intraoperative adjustment of treatment plan and prediction of tissue change of the prostate have potential for improving oncological outcomes in the patients with localized prostate cancer treated with ultrasound-guided high intensity focused ultrasound
S. Shoji, M. Nakano, T. Tomonaga, T. Terachi, T. Uchida (Japan)

PP-27 MR-guided focal laser ablation for prostate cancer followed by radical prostatectomy: Validation of MR predicted ablation volume
J.G.R. Bomers, E.B. Cornel, S.F.M. Jenniskens, C.A. Hulsbergen - van de Kaa, J.A. Witjes, J.P.M. Sedelaar, J.J. Fütterer (The Netherlands)

PP-28 MR-guided focal cryoablation of prostate cancer recurrence following radiotherapy: Short term follow-up
J.G.R. Bomers, S.F.M. Jenniskens, C.G. Overduin, H. Vergunst, E.N.J.T. van Lin, F. de Lange, E.B. Cornel, J.O. Barentsz, J.P.M. Sedelaar, J.J. Fütterer (The Netherlands & Germany)

PP-29 Focal HIFU (Focal One®) treatment of localized prostate cancer diagnosed with MRI-ultrasound fusion targeted biopsies (Koelis®): Preliminary results
P. Nevoux, E. Potiron, T. Rousseau, G. Le Coguic, G. Aillet, J. Lacoste (France)

PP-30 High intensity focused ultrasound in the treatment of localized prostate cancer: A registry experience
S. Guillaumier, L. Dickinson, N. McCartan, H. Stone, M. Thiruvel, Y. Fatola, R. Scott, R. Hindley, M. Emberton, H. Ahmed (United Kingdom)

PP-31 Focal application of low-dose-rate brachytherapy for prostate cancer: An ethics approved pilot study
S.S. Mahdavi, W.J. Morris, S.E. Salcudean, S.D. Chang, P. Kozlowski, I.T. Spadinger (Canada)

PP-32 Needle biopsy performed in a tertiary care center results in significantly less clinically relevant undergrading of prostate cancer
A. Mortezavi, E.X. Keller, K. Saba, C. Poyet, J. Bachofner, C. Fankhauser, P.J. Wild, T. Sulser, D. Eberli (Switzerland)

PP-33 Trans-peritoneal robot-assisted laparoscopic high intensity focused ultrasound for targeted therapy of the prostate and bladder: Novel approach
T. Matsugasumi, A.L. de Castro Abreu, S. Leslie, S. Shoji, A. Marien, S. Chopra, Y. Ma, I.S. Gill, O. Ukimura (USA)

PP-34 CCP score stratifies risk for prostate cancer patients at biopsy: Initial commercial results
M.K. Brawer, E.D. Crawford, N. Shore, P.T. Scardino, J.W. Davis, J. Tward, L. Harrison, K. Moyes, L. Fitzgerald, S. Stone (USA)

PP-35 Concurrence of Cell Cycle Progression (CCP) scores in paired lesions from radical prostatectomies
A.L. de Castro Abreu, E. Broxham, O. Ukimura, M.E. Gross (USA)

PP-36 Nerve sparing HIFU: Clinical experience with the EDAP Ablatherm^® device
D.O. Chinn, A. Blana (USA & Germany)

PP-37 The value of MR-guided focal cryoablation of recurrent prostate cancer after previous salvage therapy and radiotherapy
S.F.M. Jenniskens, J.G.R. Bomers, F. Witjes, H. Vergunst, M. Sedelaar, J.J. Fütterer (The Netherlands)

PP-38 Validation of an RNA Cell Cycle Progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort
M.K. Brawer, J.M. Cuzick, S. Stone, G. Fisher, Z.H. Yang, B. North, D. Berney, L. Beltran, D. Greenberg, H. Møller, J.E. Reid, A. Gutin, J.S. Lanchbury, P.T. Scardino (USA & United Kingdom)

PP-39 The role of early repeated biopsies with MRI-ultrasound fusion system in the selection process of patients eligible for Active Surveillance after a first TRUS-guided 12 biopsies scheme. A single-center prospective study
P. Nevoux, J. Lacoste, T. Rousseau, G. Le Coguic, G. Aillet, E. Potiron (France)

PP-40 Novel convective thermal water vapor therapy for prostate cancer: Uniquely suited to zonal anatomy of the prostate – Preliminary gross and microscopic findings using ex-vivo and acute in-vivo, surgical ablative studies
L. Mynderse, C. Dixon, C. Cabanas, E. Rijo Cedano, C. Huidobro, T. Larson (USA, Paraguay, Dominican Republic, Chile)

PP-41 Magnetic Resonance Imaging (MRI) – Guided transurethral ultrasound ablation of prostate cancer: Midterm outcomes of a phase I clinical trial
I.V. Popeneciu, M. Billia, J. Hafron, M. Burtnyk, T.H. Kuru, G. Hatiboglu, M. Roethke, H.-P. Schlemmer, J. Relle, J. Chin, M. Hohenfellner, S.A. Pahernik (Germany, Canada & USA)

PP-42 Practice patterns in the use of focal therapy for prostate cancer: An update from the COLD registry
V. Mouraviev, A. Ross, S. Jones (USA)

PP-43 MRI fusion guided salvage focal seed implant for post IMRT recurrence in prostate cancer
K. Miki, S. Bando, S. Egawa (Japan)

PP-44 Macro and micro effects of IRE assessed on 3D histo-pathology of the prostate
W. van den Bos, D.M. de Bruin, B.G. Muller, I.M. Varkarakis, A.A. Karagiannis, P.J. Zondervan, M.P. Laguna Pes, T.M. de Reijke, R.R. Jurhill, C.D. Savci, J.J.M.C.H. de la Rosette (The Netherlands & Greece)

PP-45 Understanding multifocality in prostate cancer and clonal origin of metastasis
M. Alemozaffar, K. Mundbjerg, S. Chopra, P. Nichols, M. Aron, O. Ukimura, G. Liang, I. Gill (USA)

PP-46 Magnetic Resonance Imaging - guided focal laser ablation for prostate cancer: Phase I trial
A. George, A. Hoang, S. Rais-Barhrami, A. Walton-Diaz, A. Rastinehad, P. Choyke, B. Turkbey, B. Wood, P. Pinto (USA)

PP-47 5-alpha reductase inhibitors in patients on active surveillance: Impact on disease progression and curative intervention
A.L. de Castro Abreu, I. Gill, D. Bahn, S. Shoji, A. Marien, J. Cai, S. Chopra, O. Ukimura (USA)

PP-48 Does the grade hotspot match the volume hotspot? A 3-D model reconstructed using template prostate mapping biopsies from the MRC PROMIS trial
A. El-Shater Bosaily, M. Valerio, Y. Hu, A. Freeman, C. Jameson, L. Brown, R. Kaplan, D. Barratt, C. Parker, R. Hindley, M. Emberton, H. Ahmed (United Kingdom)

PP-49 WITHDRAWN

PP-49A Comparison of sexual quality of life following whole and focal high-intensity-focused ultrasound for localized prostate cancer
M. Kimura, S. Muto, S. Isotani, K. Saito, I. Hisamitsu, R. Yamaguchi, S. Horie (Japan)

POSTER SESSION 3: Kidney

---

PP-50 Comparison of radiation dose from conventional and triple bolus CT urography protocols in the diagnosis and management of renal cortical neoplasms
Z. Okhunov, G. Abedi, C. Lall, K. Babaian, M. del Junco, M. Helmy, J. Landman (USA)

PP-51 Virtual partial nephrectomy analysis: Anatomical operation planning using computational three-dimensional model
S. Isotani, H. Shimoyama, Y. Isao, K. Kitamura, M. Kimura, T. China, S. Keisuke, S.-I. Hisasue, H. Ide, S. Muto, O. Ukimura, R. Yamaguchi, S. Horie (Japan & USA)

PP-52 Whole lesion quantitative CT evaluation of renal cell carcinoma: Differentiation of clear cell from papillary renal cell carcinoma
V. Duddalwar, F. Chen, H. Huhdanpaa, B. Desai, D. Hwang, S. Cen, A. Sherrod, J.-C. Bernhard, M. Desai, I. Gill (USA)

PP-53 Outpatient renal mass biopsy using image fusion of real-time US with contrast CT/MRI guidance: Pilot study
A.L. de Castro Abreu, S. Chopra, C. Beckler, M. Aron, M. Desai, S. Daneshmand, I. Gill, O. Ukimura (USA)

PP-54 Radiosurgery for lung metastases secondary to renal cell carcinoma
A. Lederman, M. Loksen, T. Lowinger, A. Khaleel, D. Izon, G. Lederman (USA)

PP-55 Novel multi-sensor umbrella probe for a more accurate temperature monitoring during loco-regional chemo-hyperthermia in bladder cancer
M. Westendarp, A. Bakker, H. Crezee, D. Geijsen, G. Schooneveldt, J. de la Rosette, T. de Reijke (The Netherlands)

PP-56 Our initial experience with cryoablation of small renal masses
F. Hongo, Y. Naya, Y. Yamada, T. Ueda, T. Nakamura, K. Kamoi, K. Okihara, O. Tanaka, K. Yamada, T. Miki (Japan)

PP-57 Percutaneous cryoablation of renal tumors: Outcomes of treatment and evaluation of renal function
S. Bando, J. Miki, K. Miki, K. Simizu, K. Kishimoto, S. Egawa (Japan)

PP-58 Avoiding nephrectomy and consecutive hemodialysis by single-fraction radiosurgery using cyberknife for the treatment of renal cell carcinoma: Initial results
M. Staehler, B. Schlenker, P. Nuhn, A. Karl, A. Roosen, C. Stief, B. Wowra, A. Muacevic (Germany)

PP-59 Long-term, single-institution follow-up of radiofrequency ablation effectiveness in the treatment of patients with hereditary renal carcinoma
J. Rothwax, A. Metwalli, H. Amalou, M. Taylor, A. George, W.M. Linehan, B. Wood (USA)

PP-60 Boiling histotripsy ablation of de novo renal tumors in the Eker rat
G.R. Schade, Y.-N.Wang, S. D’Andrea, J.H. Hwang, D.W. Lin, M.R. Bailey, T.D. Khokhlova (USA)

PP-61 Irreversible electroporation of the porcine kidney: Temperature development and distribution
P.G.K. Wagstaff, A. Ingels, D.M. de Bruin, W. van den Bos, P.J. Zondervan, R. Verdaasdonk, J.J.M.C.H. de la Rosette, M.P. Laguna Pes (The Netherlands)

PP-62 WITHDRAWN

PP-63 Is cryoablation for renal cell cancers greater than 4cm a viable treatment option?
A. Mukherjee, R.S. Khan, D. Alcorn (United Kingdom)